Страна: Канада
мова: англійська
Джерело: Health Canada
TRYPTOPHAN
BAUSCH HEALTH, CANADA INC.
N06AX02
TRYPTOPHAN
750MG
TABLET
TRYPTOPHAN 750MG
ORAL
100
Prescription
MISCELLANEOUS ANTIDEPRESSANTS
Active ingredient group (AIG) number: 0111038005; AHFS:
APPROVED
2021-06-11
_Pr_ _TRYPTAN_ _®_ _ L-Tryptophan Product Monograph Page 1 of 15_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR TRYPTAN ® L-Tryptophan 250 mg; 500 mg; 750 mg tablets 1 g Tablets 500 mg Capsules Oral Adjunct in the Management of Affective Disorders Bausch Health, Canada Inc. Date of Initial Authorization: 2150 St-Elzear Blvd. West February 23, 1994 Laval, Quebec H7L 4A8 Date of Revision: June 9, 2021 Submission Control Number: 247785 _ _ _Pr_ _TRYPTAN_ _®_ _ L-Tryptophan Product Monograph Page 2 of 15_ RECENT MAJOR LABEL CHANGES NONE TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES .................................................................................... 2 TABLE OF CONTENTS ......................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION.............................................................. 4 1 INDICATIONS............................................................................................................. 4 2 CONTRAINDICATIONS .............................................................................................. 4 4 DOSAGE AND ADMINISTRATION ............................................................................. 4 4.2 Recommended Dose and Dosage Adjustment ................................................... 4 4.4 Administration.................................................................................................... 4 5 OVERDOSAGE .......................................................................................................... 5 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ....................... 5 7 WARNINGS AND PRECAUTIONS ............................................................................. 6 8 ADVERSE REACTIONS ............................................................................................. 7 8.1 Adverse Reaction Overview ............. Прочитайте повний документ